Transforming Your Life After 50 Through Microdosing with Cesar Marin

What’s up psychedelic investors! Today we’re finally going to cover the long anticipated NUMIStock. Numinus Wellness is a psychedelic Medicines company using a variety of compounds like psilocybin, MDMA and ketamine to treat for addiction, PTSD, depression and more. You can find the NUMI Stock on the TSX Venture exchange under the ticker symbol NUMI. NUMI stock is currently trading around 1$ Canadian, with a market cap of around $200 million. If you don’t want to purchase NUMI individually, Numinus can also be partially owned through an ETF like Horizons Psychedelic Stock Index or the upcoming Advisor Shares Plant Medicine ETF.

In this video we will cover the problems Numinus is trying to solve, their flagship programs, their financials, and finally the risks for the company. Numinus Wellness is one of the first psychedelic stocks we covered on this channel and the company has advanced quite nicely in the past few months, making it an interesting pick for the shroom boom!

Time Stamps
0:00 – Intro
1:20 – What Problem is Numinus trying to solve?
3:22 – NuMi Ketamine Treatments for Depression
4:50 – MDMA to treat PTSD
6:24 – Numinus Wellness Treating Addiction with Psilocybin
7:48 – Special Access Trials for MDMA and Psilocybin
9:02 – Psilocybin Extraction from Magic Mushrooms
9:39 – Financials and Cash on Hand
11:29 – Risks

https://www.newswire.ca/news-releases/numinus-wellness-closes-q1-2021-with-strong-cash-position-and-industry-firsts-867457159.html?fbclid=IwAR3gKruRdmOGIBZeRmS_xU-R_0J4WehW5TodKLx7SWK19DdpEeoZhM8O-2c#:~:text=Achievedcashbalanceof4915209,(1928737)forQ12021

So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

If you want to collaborate, send us an email!
thepsychedelicinvestor@gmail.com

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
​…
​
https://benzinga.grsm.io/thepsychedel
​…
​

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#NuminusWellness #NUMIStock #MindMed

Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20

Join our Newsletter (scroll to the bottom of the page and sign up):
https://psychedelicspotlight.com/

Wesana Health May Sell Clinics to Focus Solely on Drug Development: An Analysis
https://psychedelicspotlight.com/wesana-health-may-sell-clinics-to-focus-solely-on-drug-development-an-analysis/

Why Field Trip Health Is Dividing in Two — and What This Means for Investors
https://psychedelicspotlight.com/field-trip-health-dividing-two-companies-reunion-neuroscience/

In today’s episode of the Psychedelic Investor, I discuss two major stories. First, is the news that Field Trip Health (Nasdaq: FTRP, TSX: FTRP) will be splitting into two separate companies.
Next, Wesana Health (CSE: WESA, OTCQB: WSNAF) announced that they are considering selling all of their non-drug development assets, including their Psychedelic Therapy clinics.

Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PSYCBiz
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@psycbiz
@psycspotlight

To read more about the Field Trip situation: https://psychedelicspotlight.com/field-trip-health-dividing-two-companies-reunion-neuroscience/

To read more about the Wesana situation: https://psychedelicspotlight.com/wesana-health-may-sell-clinics-to-focus-solely-on-drug-development-an-analysis/

Field Trip Press Release: https://www.globenewswire.com/news-
release/2022/04/28/2432105/0/en/Field-Trip-Health-Ltd-Announces-Intention-to-Separate-the-Field-Trip-Discovery-and-Field-Trip-Health-Divisions-Into-Two-Independent-Public-Companies.html
Wesana Press Release: https://ir.wesanahealth.com/news-events/press-releases/detail/41/wesana-announces-singular-focus-on-drug-development

Field Trip Health:
In a surprise move, Field Trip Health Ltd. announced on Thursday that they will be separating their company into two independent publicly traded entities.
Assuming the ratification of shareholders and regulatory approval, come July 2022, Field Trip Health will be no more. From its ashes will rise Reunion Neuroscience Inc, and Field Trip Health and Wellness Ltd.
Reunion will be the successor to Field Trip’s Discovery division, which was the part of the company which worked on next-generation psychedelics. This includes FT-104, a psilocybin-like compound that is a prodrug to 4-HO-DiPT, and the company’s FT-200 series of psychedelics, which they call third-generation.

Wesana:
On Thursday, Wesana Health made a major announcement. Following a planned strategic review of their assets, Wesana is considering options “including, but not limited to, a sale of all the assets under the care delivery division,” including all of their psychedelic therapy clinics.
The core reasoning, according to the press release, is that Wesana wants to focus its efforts entirely on its drug development division.
Prior to this announcement, Wesana was operating under a philosophy centered on “developing the novel therapies of tomorrow and delivering new care paradigms today.” If this strategic review does result in the sale of their clinics and other today-focused ventures, then Wesana will be decidedly much more focused on tomorrow.

@psycspotlight #wesana #psychedelicstocks #thepsychedelicinvestor